Parathyroid carcinoma visualized by gallium-67 citrate scintigraphy

Area of Science:

• Nuclear medicine
• Oncology
• Endocrinology

Background:

• Primary hyperparathyroidism is often caused by parathyroid adenoma, but can rarely be due to parathyroid carcinoma.
• Differentiating parathyroid carcinoma from adenoma is crucial for appropriate patient management.
• Current diagnostic methods may not always reliably distinguish between benign and malignant parathyroid lesions.

Observation:

• A patient with primary hyperparathyroidism presented with a palpable neck tumor exhibiting abnormal uptake of gallium-67 (67Ga) citrate.
• Pathological examination of the resected tumor confirmed parathyroid carcinoma invading the thyroid gland.
• In contrast, nine patients with parathyroid adenoma showed negative uptake of 67Ga citrate in their respective tumors.

Findings:

• Gallium-67 scintigraphy demonstrated abnormal tracer uptake in a confirmed case of parathyroid carcinoma.
• No significant uptake of 67Ga citrate was observed in patients with benign parathyroid adenomas.
• These findings suggest a potential role for 67Ga scintigraphy in identifying malignant parathyroid disease.

Implications:

• 67Ga scintigraphy may serve as a valuable non-invasive tool to differentiate parathyroid carcinoma from benign parathyroid adenoma.
• Improved diagnostic accuracy could lead to earlier detection and more effective treatment strategies for parathyroid cancer.
• Further research is warranted to validate these findings in larger patient cohorts and establish the sensitivity and specificity of 67Ga scintigraphy for parathyroid carcinoma.